Literature DB >> 16457812

Trypsins and their role in carcinoma growth.

Pia Nyberg1, Merja Ylipalosaari, Timo Sorsa, Tuula Salo.   

Abstract

There are more than 100 distinct types of cancer, and subtypes can be found within specific organs. Cancer progression is a complex multi-step process. These steps reflect alterations that drive the progressive transformation of normal cells into highly malignant ones. One critical step in tumor growth and invasion is the proteolytic processing of the extracellular matrix environment. The degradation of the extracellular matrix not only enables cell migration, invasion, and metastasis formation, but also affects cell behavior in multiple ways; on one hand by cleaving extracellular matrix bound growth factors and on the other hand by inhibiting angiogenesis into the tumor by liberating cryptic endogenous inhibitors of angiogenesis. Serine proteases and matrix metalloproteases are families of proteolytic enzymes involved in physiological and pathological extracellular matrix and basement membrane processing. In this review, we will focus on the role and activation of trypsinogens, a family of serine proteases, in cancer progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16457812     DOI: 10.1016/j.yexcr.2005.12.024

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  25 in total

Review 1.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

Review 2.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

3.  Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells.

Authors:  Tariq Shah; Ioannis Stasinopoulos; Flonne Wildes; Samata Kakkad; Dmitri Artemov; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2011-09-22       Impact factor: 4.044

Review 4.  Trypsin isozymes in the lobster Panulirus argus (Latreille, 1804): from molecules to physiology.

Authors:  Erick Perera; Leandro Rodríguez-Viera; Rolando Perdomo-Morales; Vivian Montero-Alejo; Francisco Javier Moyano; Gonzalo Martínez-Rodríguez; Juan Miguel Mancera
Journal:  J Comp Physiol B       Date:  2014-09-06       Impact factor: 2.200

5.  Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.

Authors:  Bonan Lin; Xiaomeng Zhou; Shuye Lin; Xiaoyue Wang; Meiying Zhang; Baoping Cao; Yan Dong; Shuai Yang; Ji Ming Wang; Mingzhou Guo; Jiaqiang Huang
Journal:  J Mol Med (Berl)       Date:  2017-08-26       Impact factor: 4.599

6.  Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin.

Authors:  Moh'd A Salameh; Alexei S Soares; Duraiswamy Navaneetham; Dipali Sinha; Peter N Walsh; Evette S Radisky
Journal:  J Biol Chem       Date:  2010-09-22       Impact factor: 5.157

Review 7.  Biologic mechanisms of oral cancer pain and implications for clinical therapy.

Authors:  C T Viet; B L Schmidt
Journal:  J Dent Res       Date:  2011-10-04       Impact factor: 6.116

8.  Potential contributions of heat shock proteins to temperature-dependent sex determination in the American alligator.

Authors:  S Kohno; Y Katsu; H Urushitani; Y Ohta; T Iguchi; L J Guillette
Journal:  Sex Dev       Date:  2009-11-20       Impact factor: 1.824

9.  Effect of anti-fibrinolytic therapy on experimental melanoma metastasis.

Authors:  Jennifer M Kirstein; Kevin C Graham; Lisa T Mackenzie; Danielle E Johnston; Leslie J Martin; Alan B Tuck; Ian C MacDonald; Ann F Chambers
Journal:  Clin Exp Metastasis       Date:  2008-12-12       Impact factor: 5.150

10.  Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109.

Authors:  Alexandra Hockla; Derek C Radisky; Evette S Radisky
Journal:  Breast Cancer Res Treat       Date:  2009-12-25       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.